613 related articles for article (PubMed ID: 11912124)
1. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
3. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
4. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
He Q; Huang Y; Sheikh MS
Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
[TBL] [Abstract][Full Text] [Related]
6. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
8. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.
Qin JZ; Bacon PE; Chaturvedi V; Bonish B; Nickoloff BJ
Exp Dermatol; 2002 Dec; 11(6):573-83. PubMed ID: 12473065
[TBL] [Abstract][Full Text] [Related]
9. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2.
Sinicrope FA; Penington RC
Mol Cancer Ther; 2005 Oct; 4(10):1475-83. PubMed ID: 16227396
[TBL] [Abstract][Full Text] [Related]
10. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
Ravi R; Bedi GC; Engstrom LW; Zeng Q; Mookerjee B; Gélinas C; Fuchs EJ; Bedi A
Nat Cell Biol; 2001 Apr; 3(4):409-16. PubMed ID: 11283615
[TBL] [Abstract][Full Text] [Related]
11. Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis.
He Q; Montalbano J; Corcoran C; Jin W; Huang Y; Sheikh MS
Oncogene; 2003 May; 22(17):2674-9. PubMed ID: 12730681
[TBL] [Abstract][Full Text] [Related]
12. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
13. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
15. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
16. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
17. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
18. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation.
Kim M; Park SY; Pai HS; Kim TH; Billiar TR; Seol DW
Cancer Res; 2004 Jun; 64(12):4078-81. PubMed ID: 15205314
[TBL] [Abstract][Full Text] [Related]
20. Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status.
Kim IY; Park SY; Kang Y; Thapa D; Choi HG; Kim JA
Arch Pharm Res; 2011 Feb; 34(2):323-30. PubMed ID: 21380817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]